Metanoia Press · In preparation
An atypical psychedelic, and a serious cardiac risk
Iboga is an atypical psychedelic. Its effects are long, and its metabolite lingers in the body for days. Its character is described as dreamlike rather than visionary, and most human research on it was done in people with opioid dependence or with brain injury. It also carries a real cardiac risk that must be respected. Our forthcoming book keeps the evidence and the danger in the same frame, and roots both in the Central African tradition that has used it for generations.
What the Book Will Cover
Root, molecule, tradition, risk
The plant
Tabernanthe iboga of Gabon, its root bark, and its principal alkaloid, ibogaine, with its long-acting metabolite noribogaine.
The Bwiti
The Central African spiritual tradition, initiation and community ritual, for which iboga is a sacrament, not a drug.
Addiction & the brain
Why an "atypical" psychedelic has drawn attention in addiction research, and how limited that evidence is.
The cardiac risk
The heart-rhythm danger that makes medical screening and monitoring non-negotiable.
The science in brief
Ibogaine acts on an unusually broad set of targets, NMDA, opioid, sigma, and serotonin systems. In rat experiments, ibogaine raised the activity of the genes for BDNF and GDNF, and the protein results were narrower. No human study the page found measured them. Its subjective character is closer to a long dream than a classic "trip." A 2024 open-label study of magnesium-buffered ibogaine in 30 special-operations veterans, nearly all with mild traumatic brain injury, published in Nature Medicine, reported improvements in disability, PTSD, depression, and anxiety. The study's protocol included magnesium infusions and cardiac monitoring. It had no control group, most participants already met criteria for PTSD, and its authors call for controlled trials to validate the findings.
The risk that defines the protocol
Ibogaine can dangerously prolong the heart's QT interval, and deaths have occurred in unmonitored settings. This is why serious clinical work uses cardiac screening and monitoring, and why iboga is emphatically not something to approach casually. "Natural" is not the same as "safe."
Addiction research has taken an interest in ibogaine, but we have not identified rigorous randomized trials in this area. We report it as what it is: early, serious, and not yet settled.
Reliability: pharmacology and cardiac risk are well established (strong). Efficacy evidence is early, mostly observational (limited). The clinical results described here come from people with a diagnosis and do not describe healthy adults. Full sources will accompany the finished book.
Read the published book Safe use & contraindications See the whole family